February 19th 2025
According to ImmunityBio, shipments or rBCG are set to begin immediately via the EAP.
February 16th 2025
Managing recurrence following bladder-sparing treatment
June 23rd 2023"If there’s recurrence of muscle-invasive bladder cancer within the bladder, you can perform salvage cystectomy at that point…. It is a bit more complex, so it’s great to have a high-volume surgeon who has performed these before," says Sophia C. Kamran, MD.
Bladder-sparing treatments show noninferior OS vs radical cystectomy in BCG-unresponsive NMIBC
June 19th 2023“Our results suggest that bladder-sparing treatments may be a safe approach in selected patients. Survival outcomes were not inferior compared to early radical cystectomy," says Wei Shen Tan, MD.
Emulating target trials using observational evidence to inform clinical decision-making
June 2nd 2023"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Treatment Options for Non-Muscle-Invasive Bladder Cancer
May 22nd 2023Eric A. Singer, MD, MA, FACS, an expert urologic oncologist, discusses the use of Bacillus Calmette-Guerin (BCG) as a first-line therapy for non-muscle-invasive bladder cancer (NMIBC), and reviews subsequent treatment options for patients with high-risk NMIBC who are found to be unresponsive to BCG.
Dr. Daneshmand on safety of TAR-200 intravesical chemo delivery system in NMIBC
May 22nd 2023Siamak Daneshmand, MD, discusses the safety profile for TAR-200 from the phase 2b SUNRISE-1 trial, which explored the novel intravesical chemo delivery system in patients with BCG-unresponsive on–muscle-invasive bladder cancer.